Evommune, Inc.

Overview

Evommune, Inc. Explainer 1. How the company got here Evommune, Inc. was founded in 2020 by a team of experienced drug developers, including Luis Peña, who previously led a successful company called Dermira. The company was established with the goal of tackling chronic inflammatory diseases, which are linked to over 100 autoimmune conditions and are a leading cause of death globally. Evommune has since raised significant funding, including private capital and an initial public offering (IPO) in November 2025, to support its research and development efforts. 2. What it actually does Evommune is a biotechnology company focused on creating new medicines for people suffering from chronic inflammatory diseases. These are long-lasting conditions where the body's immune system mistakenly attacks its own tissues, causing damage and discomfort. The company's main goal is to develop therapies that not only relieve symptoms but also address the underlying causes of these diseases, aiming to improve patients' quality of life and prevent long-term health problems. 3. Business Lines EVO756 (MRGPRX2 Antagonist) Evommune is developing EVO756, a potential treatment that works by blocking a specific protein called MRGPRX2. This protein is found on certain cells in the body, like mast cells, and plays a role in triggering inflammatory responses. By blocking MRGPRX2, EVO756 aims to reduce the inflammation associated with conditions like chronic spontaneous urticaria (hives) and atopic dermatitis (eczema). While initially explored for chronic spontaneous urticaria, Evommune has decided to focus its development efforts for EVO756 on atopic dermatitis and migraine. EVO301 (IL-18 Binding Protein Fusion Protein) Evommune's other main product candidate is EVO301, which is a type of therapy known as a fusion protein. It is designed to target and block a substance called IL-18, which is a key player in causing inflammation in the body. EVO301 is being developed to treat conditions such as atopic dermatitis and ulcerative colitis (a type of inflammatory bowel disease). The company is planning to start a larger clinical trial for EVO301 in mid-2027 and is also exploring its use for other inflammatory conditions. 4. What management is betting on now Evommune's current strategy is centered on advancing its EVO301 program for atopic dermatitis and exploring its potential in other inflammatory conditions like ulcerative colitis. The company is also continuing to investigate EVO756 for atopic dermatitis and migraine, despite discontinuing its development for chronic spontaneous urticaria. Management is prioritizing these programs due to their potential to address significant unmet needs in chronic inflammatory diseases, leveraging their team's extensive experience in drug development to navigate the complex process of bringing new therapies to market.